News | ASTRO | October 24, 2020

ASTRO's Exhibit Hall Only Day Draws Over 1,000 Attendees

Conference programming for ASTRO20 began today, and runs through October 29

Conference programming for ASTRO20 began today, and runs through October 29 #ASTRO20

October 24, 2020 — The American Society of Radiation Oncology's (ASTRO) 62nd Annual Meeting launched its Exhibit Hall Only Day yesterday, a new event one day before programming begins, to provide more time for attendees to network and interact with exhibitors. More than 1,000 attendees from 60 countries participated in Exhibit Hall Only Day yesterday, visiting our more than 110 exhibitors.

Traci Conley, regional account manager with Standard Imaging, Inc. shared, “This is absolutely amazing! I stopped in the lounge this morning and it seems everyone shares the opinion…this is engaging and user-friendly. Well done to the entire ASTRO team!”

“This has been a great experience and exceeds my expectations and past experience of a virtual meeting,” said Kelly Graber, Stryker senior program manager-Tradeshow.

“This virtual Exhibit Hall is one of the best platforms I've experienced this year, and we're pleased with the amount of exposure and access it has given us. The ASTRO team always organizes a great event with quality scientific content mixed with vendor participation and social activities to provide everyone with an exceptional experience each year,” said Melanie Benton, director, Marketing, at Mevion Medical Systems.

ASTRO20 runs October 24-28, 2020, via an interactive virtual platform. The meeting, Global Oncology: Radiation Therapy in a Changing World, will feature reports from the latest clinical trials; panels on global oncology, health disparities and the novel coronavirus; and an immersive attendee experience in a virtual convention center.

Originally planned as an on-site meeting in Miami, the ASTRO 2020 Annual Meeting was moved to a web-based platform due to safety concerns associated with the COVID-19 pandemic. Given the large volume of new science to be unveiled, the content will be available for 30 days after the meeting ends.

"Cancer doesn’t wait, even during a pandemic. With the health and safety of cancer patients in mind, we chose to invest in an interactive platform so that we can offer attendees a complete meeting experience,” said ASTRO President Thomas J. Eichler, M.D., FASTRO. “Attendees will be able to engage with each other on live video and chat platforms and access more than 2,500 abstracts. We will have live, on-demand and interactive sessions to showcase the latest research and best practices in cancer treatment. Recognizing that many meetings were cancelled or abbreviated this year, we enhanced our educational program and will have more than 200 hours of continuing medical education (CME) credits available for 30 days after the meeting ends.”

The meeting platform includes a digital rendering of the Miami Beach Convention Center that attendees can navigate to interact with other attendees and ASTRO leadership, visit networking lounges, participate in job interviews and attend live and on-demand sessions.

For more information: ASTRO20

Related Content

F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

News | Molecular Imaging | February 22, 2021
February 22, 2021 — Molecular imaging
Radiology, radiation therapy, PACS, Enterprise image, X-ray, DR Systems, CT, MRI, contrast, ultrasound, VNA, product comparisons, comparison charts on ITN magazine.
Feature | February 17, 2021
Imaging Technology News (ITN) maintains more than 40
Immunotherapy-based precision medicine clinical trials being developed

Getty Images

News | Prostate Cancer | February 16, 2021
February 16, 2021 — Black men die more often of prostate cancer yet, paradoxically, have greater survival benefits fr

Chart courtesy of the American Cancer Society

News | Breast Imaging | February 08, 2021
February 8, 2021 — Cancer ranks as a leading cause of death in every country in the world, and, for the first time,
Phase III clinical trial of men with a clinical suspicion of prostate cancer finds MRI with targeted biopsies to be more accurate at diagnosis and less intrusive than current standard
News | Magnetic Resonance Imaging (MRI) | February 08, 2021
February 8, 2021 — The results of a Phase III randomized clinical trial have shown that when it comes to detecting cl

Images in 69-year-old man with biopsy-confirmed Gleason score 7 (3+4) prostate cancer. (a) Pretreatment axial T2-weighted fast spin-echo MRI scan (repetition time msec/echo time msec, 3820/97) shows tumor in midline anterior transition zone (arrow). (b) Intraoperative MRI scan shows contoured rectal wall (red line), prostate margin (blue outline), and region of interest (orange outline). Because the urethra was included in planned treatment volume, a suprapubic catheter was placed for continuous bladder drainage during treatment. (c) Intraoperative MRI scan shows focused ultrasound beam path (blue) overlaid on treatment plan. Rectangles illustrate each sonication spot. (d) Thermal map image obtained during treatment with heat deposition color coded in red overlaid on sonication spot. (e) Axial gadopentetate dimeglumine-enhanced MRI scan (230/2.97) obtained immediately after treatment shows devascularized ablated volume (arrows). (f) Corresponding T2-weighted fast spin-echo MRI scan (3820/97) at 5 months after ablation shows complete involution of transition zone. All seven cores from treatment area margins were negative for cancer at biopsy. Image courtesy of the Radiological Society of North America

News | Prostate Cancer | February 05, 2021
February 5, 2021 — A technique that delivers...
Real Time Imaging Technologies LLC iannounced that it has received U.S. Patent No. 10,898,070 IMAGING APPARATUS AND METHODS which covers the company’s methods for incorporating microlens into X-ray imaging detectors that enables significantly lower radiation dose without compromising image resolution.

Getty Images

News | Radiation Dose Management | February 05, 2021
February 5, 2021 —